Novo Nordisk Partners with Septerna in $2.2 Billion Deal for Oral Obesity Therapies

The collaboration aims to develop four GPCR-targeted small-molecule treatments, diversifying Novo Nordisk’s portfolio amid rising competition from Eli Lilly.